We found that SFRP2 promoter methylation in whole blood is a promising prognostic factor for several cancer outcomes, such as stages, lymph node invasion and CRC recurrence, while SFRP2 promoter methylation in tumors is a potential predictor of treatment response. This evidence concerns the gene SFRP2 and colorectal carcinoma.